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Abstract; The expression of EGFR and p53 has not been adequately studied as a prognostic tool in urinary bladder tumors. 
We analyzed 74 bladder cancer samples from Egypt for EGFR and p53 expression using immunohistochemistry. The tumors 
were of different histological types, grades and clinical stages, and with established lymph node status. Almost 61% of the 
tumors showed positive membranous EGFR expression and 74.3% had positive nuclear staining of p53. Analysis of 
correlation of the IHC staining with clinical variables showed a significant correlation only between EGFR expression and 
histological type (p=0.002, ANOVA), in that the expression was higher in squamous cell carcinomas than in other histological 
types. There were no significant correlations between p53 or EGFR with the other clinicopathological variables, including age, 
sex, staging, grading, and lymph node status. Further studies are needed to determine if EGFR and p53 might be used as 
prognostic tools in bladder cancer. 
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Introduction 
Bladder cancer is a moderately prevalent disease, with 
10,200 new cases and 5,000 annual deaths occurring in 
the UK alone [1]. Prognosis depends on tumor stage and 
grade; higher stage, muscle-invading tumors have poorer 
prognosis. The results of radical surgery in patients with 
lower stage disease are remarkable [2], but the overall 
five-year survival following radical treatment for tumors of 
all stages remains about 40-50% [3]. 
 
Epidermal growth factor receptor (EGFR, also known as 
ErbB1) is a member of the ErbB family of receptors, which 
are important for relaying signals that regulate cell 
proliferation, differentiation, motility and apoptosis. The 
other family members are ErbB2, ErbB3 and ErbB4.  EGFR 
is a 170-kDa trans-membrane protein that exhibits intrinsic 
tyrosine kinase activity when it binds one of its cognate 
ligands [4,5]. Activation of EGFR leads to a wide variety of 
biological responses, such as proliferation, differentiation, 
migration, modulation of apoptosis, invasion, and 
metastasis, and under pathophysiological conditions it 
contributes to progression of different malignancies 
[6,7,8]. Thus, strong expression of EGFR appears to be a 
negative prognostic factor in several human malignancies, 
including breast and bladder cancer [9,10], which 
prompted us to select EGFR as the first marker to be 
tested. 
 
Another key protein in human carcinogenesis is the 
tumor suppressor p53. Mutation in the wild type p53 gene 
and nuclear accumulation of non-functional p53 protein 
reflect compensatory over-expression of the protein [11]. 
p53 is a nuclear phosphoprotein functioning as a 
transcription factor. It regulates cell growth indirectly and 
inhibits cells with mutagenic breaks in the DNA from 
entering the S-phase by arresting the cell cycle in G1. The 
mutant p53 also has a longer half-life. Therefore, nuclear 
p53 protein accumulation is a common phenomenon in 
many human malignancies [12-14], and for that reason 
we selected it as a second marker in this study.  
 
 
 
 
Material and methods 
Tumor samples; We obtained samples of primary 
tumors of the urinary bladder from 74 patients ranging in 
age from 7 to 81 years. Fifty-five of the patients (74.3%) 
were males. The material was provided by the National 
Cancer Institute, Cairo (Egypt) as paraffin blocks. The key 
clinical data of the patients and their tumors are shown in 
Table 1.  
 
EGFR and p53 immunostaining 
From each sample we prepared one hematoxylin and 
eosin section and two unstained 5-µm sections for 
immunohistochemistry (IHC). IHC staining was done at 
the Department of Pathology, African Institute of 
Oncology, Sabratha, Libya. 
 
An experienced pathologist (SA) confirmed all 
histological diagnoses. IHC analysis was done using the 
automatic system (BenchMark XT, Ventana Medical 
Systems, Inc. Tucson, Arizona, USA). This fully automated 
processing of bar code-labeled slides included baking of 
the slides, solvent free deparaffinization, antigen retrieval 
in a cell conditioning buffer CC2 (mild: 36 min 
conditioning, and standard: 60 min conditioning), and 
incubation with the  monoclonal anti-EGFR antibody (clone 
3C6, Ventana Medical Systems, Inc. Tucson, Arizona, 
USA), (32 min, 37˚C). The same protocol was followed for 
staining with the monoclonal anti-p53 antibody (clone 
Do7, Ventana Medical Systems, Inc. Tucson, Arizona, 
USA). For detection we used UltraViewTM Universal DAB, 
a biotin-free, multimer-based detection system for specific 
and sensitive detection of mouse IgG, mouse IgM, and 
rabbit IgG primary antibodies. UltraView DAB includes 
UltraView Universal HRP, UltraView Universal DAB 
Inhibitor, UltraView Universal DAB Chromogen, UltraView 
Universal DAB H2O2, and UltraView Universal DAB Copper. 
Counterstaining was with hematoxylin (2021) for 4 min, 
and post-counterstaining was with bluing reagent (2037) 
for 4 min. After staining, the sections were dehydrated in 
ethanol, cleared in xylene, and covered with Mountex and 
cover slips. 
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Evaluation of EGFR staining  
The EGFR staining was evaluated by an observer 
blinded to the clinical data (AE) using regular light 
microscopy (Leitz, Laborlux K, Leitz Portugal). Only 
membranous staining was evaluated and scored (+++, 
++, +, –) [15]. In calculating the staining index known as 
membrane index (MI), both the intensity of the staining 
and the fraction of positively-stained cells were taken into 
account, using the following formula [16].  
Ι= 0 * f0 + 1 * f1 + 2 * f2 + 3 * f3 
Here I is the staining index, and f0-f3 represents the 
fraction of the cells showing a defined level of staining 
intensity (from 0 to 3). Theoretically, the index ranges 
from 0 to 3 [16]. 
 
Evaluation of p53 staining  
The nuclear staining of p53 was evaluated in a high 
intensity area by estimating the fraction of positive nuclei 
among 200 nuclei. Before analyzing the staining results, a 
few samples were analyzed twice by AE and once by NI to 
estimate intra- and inter-observer reproducibility. This was 
shown to be excellent for both EGFR and p53 
immunostaining (κ=0.782 and κ=0.832, respectively).  
 
Statistical analysis 
SPSS for Windows (16.0.2 SPSS, Inc. Chicago, Illinois, 
USA) was used for statistical analysis. Frequency tables 
were analyzed using the Chi-square test or Fisher’s exact 
test (where appropriate) with Pearson's R or likelihood 
ratio (LR) statistics to assess the significance of the 
correlation between categorical variables. Differences in 
the means of continuous variables between the groups 
were analyzed using ANOVA (analysis of variance), or non-
parametric tests (Mann–Whitney, Kruskal–Wallis) tests. In 
all analyses, p < 0.05 was regarded as significant.  
 
Results 
EGFR and p53 expression patterns are illustrated in 
Figure 1. The expression pattern of EGFR was 
predominantly membranous. Forty-five samples (60.8%) 
showed positive membranous EGFR expression, whereas 
no expression was observed in 21 samples (28.3%) and 8 
samples (10.8%) could not be evaluated. Fifty-five 
samples (74.3%) showed positive nuclear staining of p53, 
whereas 11 samples (14.8%) were negative and 8 
(10.8%) were not adequately stained. 
 
We analyzed EGFR and p53 expression in relation to all 
available clinical variables and tumor characteristics by 
univariate analysis.  The clinical variables recorded were 
age, sex, grading, staging, lymph node status, and 
histological type. A significant correlation between EGFR 
expression and histological type was observed (p=0.002, 
ANOVA). EGFR expression was higher in squamous cell 
carcinomas than in the other types of urinary bladder 
tumors. We did not observe any other significant 
correlations between p53 or EGFR expression on the one 
hand and the other clinicopathological variables on the 
other hand. 
 
 
 
 
Figure 1 Immunohistochemical staining of tumor of urinary 
bladder.  (a) Membranous expression of EGFR.  (b) Nuclear 
expression of p53 (x20 magnification) 
 
Table 1 Key characteristics of the tumors 
Variable  No. or value  Percent * 
Primary nodal status  
N0 
N+ 
Nx 
 
33 
17 
24 
 
44.6 
22.9 
32.4 
Histological grade 
I 
II 
III 
Not available 
 
6 
27 
24 
17 
 
8.1 
36.5 
32.4 
22.9 
Stage 
II 
III 
IV 
Not available 
 
15 
13 
6 
40 
 
20.2 
17.6 
8.1 
54.0 
Histological type  
Squamous carcinoma 
Transitional carcinoma 
Adenocarcinoma 
Undifferentiated  
Others
#
Unclassified 
 
20 
17 
13 
6 
17 
1 
 
27.0 
22.9 
17.5 
8.1 
22.9 
1.3 
*When applicable; Nx, unknown; NA, not available. 
#Spindle cell 
tumor, leimyosarcoma, sarcomtoid tumor, embryonal rhabdomyoma. 
 
Discussion 
Activation of proto-oncogenes and inactivation of tumor 
suppressor genes are frequently involved in tumorigenesis. 
Among other things, proto-oncogenes control normal cell 
growth pathways and cell cycle regulation. Once proto-
oncogenes undergo mutations, rearrangements, 
insertions, or amplification, they can activate genes 
(oncogenes) and result in uncontrolled cellular 
proliferation [17]. Different classes of oncoproteins have 
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been characterized at the molecular level, including 
growth factors, growth factor receptors and transcriptional 
factors. 
 
In a series of 52 small-cell carcinomas of the bladder, 
expression of EGFR in the neoplastic cells was reported to 
have a mixed membranous and cytoplasmic pattern [18]. 
In our current study, the expression EGFR was only 
membranous in all cancer samples. In their study, Wang 
et al. [18] reported that positive IHC expression of EGFR 
was observed in bladder tumors of 14/52 patients (27%): 
7 with 10% to 25% staining, 4 with 25% to 50% staining, 
1 with 50% to 75% staining, and 2 with 75% to 100% 
staining. In the present series, membranous expression or 
accumulation was observed in 60.8% (45 cases) of the 
tumor specimens, whereas 21 cases (28.3%) were 
negative and 8 cases (10.8%) were not evaluable because 
the tissue became detached after staining. This difference, 
i.e. lack of cytoplasmic expression in our study, might be 
due to technical factors. It is well known that different 
antibodies can give different staining patterns, and 
furthermore, interpretation of cytoplasmic expression is 
more subjective than membranous pattern, though the 
pictures published by Wang et al. [18] are quite 
convincing in this respect. The difference might also be 
due to the use of different target material. Small-cell 
carcinoma of the bladder is a distinct entity, and the 
expression profile in this type of lesion might be different 
from that of the usual histological types, of which the 
majority of cases in the present series consisted. All this 
makes a direct comparison between these two studies of 
limited value.  Recently, another study was published 
comprising 16 cases of squamous cell carcinomas [19]. All 
16 cases and 11/16 were positive for EGFR and p53, 
respectively. This is fully consonant with our observations, 
where squamous cell carcinomas expressed EGFR more 
often and more intensely than the other histological types. 
Also the staining pattern for EGFR was membranous in 
both of these studies and p53 was nuclear. However, we 
stress that in our series, squamous cell carcinomas 
represent a minority (27%) of all lesions. 
 
We observed significant correlations only between EGFR 
expression and the histological type of the tumors, with 
squamous cell tumors showing more intense expression. 
None of the other recorded clinical variables had any 
significant association with EGFR, including age, sex, 
grade, lymph node status, and stage. This observation is 
in agreement with a report on small-cell carcinoma of the 
urinary bladder [18]. On the basis of this small study, it is 
clearly premature to draw definite conclusions about the 
practical implications of EGFR staining in bladder cancer. 
The distinct expression in different histological types might 
have some potential value in differential diagnosis of 
problem cases, but to confirm this, we need to analyze a 
substantially larger series of well characterized cases of 
different histological types of bladder tumors. However, 
our study does not provide any direct evidence that EGFR 
staining would be of value in disease prognostication. 
 
The expression of p53 was nuclear in all tumor tissues, 
which confirms previous observations [12]. There was no 
correlation between p53 expression and any of the 
clinicopathologic characteristics recorded. Unfortunately, 
published data on p53 in bladder carcinomas are not 
sufficient to enable direct comparisons [10]. However, in 
their study of 99 transitional cell carcinomas, Vardar et al 
[10] reported a difference in p53 over-expression between 
low-grade and high grade tumors (p<0.05). There was no 
significant relationship for recurrence between p53-
positive and p53-negative groups, but there was a 
statistically significant relationship between progression 
and histological grade of the tumors. Similarly, p53 had no 
significant relationship with tumor recurrences (p>0.05), 
but its relationship with progression was statistically 
significant (p<0.05). However, we could not confirm any 
of these observations in our study. At this stage, additional 
studies are clearly needed to cast further light on the 
possible value of p53 as a prognostic and predictive 
marker in bladder cancer. 
 
To conclude, EGFR and p53 seem to be expressed in 
most bladder carcinomas, but some differences might 
exist in the expression of (at least) EGFR between the 
different histological types of these tumors. Further work 
might provide new insights that might help dividing the 
patients into subgroups with respect to their different 
management options. 
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